Panel · Use case · Market Access

Payer Dossier Red Team.

LiveRed Team Review

Stress-test a payer value dossier from HEOR, evidence, competitive and market access angles before submission.

Plan under testA payer value dossier

AnglesHEOR, access, evidence, ecosystem

ReaderHEOR and access leads

Not askedA rewritten dossier

DepthStandard, four seats

Payer Dossier Red Team is a ready-made use case for Market Access. It ships under the Red Team Review template.

For market access and HEOR leads. You get the position under test, a verdict, the challenges by angle, which survive, what would have to be true and where the dossier is weakest. Claims are cited or marked as gaps.

Add it to your library to reuse from New → From template. Edit the saved copy in your library on the service form.

The decision

Where does the value dossier for a specialty therapy fail, before it is submitted to payers?

Who attacks

The AMCP Format sets out what US formulary submissions contain, and independent bodies such as ICER publish their own assessments of value. The dossier will be read against both.

Seat	How it attacks	What it works from
HEOR Evidence Lead	Model structure, inputs and the assumptions behind the value claim.^{1Academy of Managed Care Pharmacy. AMCP Format for Formulary Submissions, Version 4.1. December 2019.,2Institute for Clinical and Economic Review. Value Assessment Framework.}	The AMCP Format and published assessment frameworks.
Global Market Access Director	How a payer committee will read the dossier and what policy it will apply.	Payer policies for similar products.
Global Value & Evidence Lead	The strength of the clinical evidence and the comparator evidence.	Systematic reviews and network meta-analyses.
Ecosystem Intelligence Orchestrator	Rival evidence and independent assessments that may undermine the claim.^{2Institute for Clinical and Economic Review. Value Assessment Framework.}	Public assessments and competitor data.

What the red team does

The model is a target. Small changes in inputs can move a value result. The report names the inputs on which the claim depends and what happens if each is wrong.^{1Academy of Managed Care Pharmacy. AMCP Format for Formulary Submissions, Version 4.1. December 2019.}

An independent assessment may arrive first. The red team asks how the dossier would look beside an independent value assessment and where the two would differ.^{2Institute for Clinical and Economic Review. Value Assessment Framework.}

Weakest point. The report names the single claim in the dossier that a payer is most likely to reject.

Recommended length

Standard

Four angles can break this plan. Standard depth gives each a seat, scores the challenges and lists mitigations and tripwires in about four pages.

You can pick another length on the form. The other two stay available.

Assumptions the red team tests

The red team lists the assumptions the plan relies on and says what would break each. Examples for this plan:

The comparator in the dossier is the one payers use in practice.
The surrogate outcome translates to the clinical outcome in the model.
The price is within the range payers have accepted for similar products.

Standards, guidance and sources

Frame

AMCP Format for Formulary Submissions, version 4.1.^{1Academy of Managed Care Pharmacy. AMCP Format for Formulary Submissions, Version 4.1. December 2019.}
ICER, value assessment framework.^{2Institute for Clinical and Economic Review. Value Assessment Framework.}

The decision practice behind the memo itself is on the template page.

What gets flagged

Any model input with no source, any comparator that payers may not use, and any claim that depends on a single trial.

What arrives

The position under test
Verdict
The challenges, by angle
Which challenges survive
The pre-mortem
What would have to be true
Mitigations and tripwires
Where the position is weakest

What it will not do

It stays adversarial and does not defend the plan. It is a stress test by AI specialists and not a vote of human experts, and the decision stays with you.

It does not re-run the economic model.

It does not defend the plan. Defenses appear only as the status of an attack.

It does not invent an attack. Each challenge rests on a cited fact or is marked as a gap.

It is not a vote of human experts. Every seat is an AI specialist, and the report says so.

References

[1] Academy of Managed Care Pharmacy. AMCP Format for Formulary Submissions, Version 4.1. December 2019. Scope and status as given in AMCP’s release; not read in full.
[2] Institute for Clinical and Economic Review. Value Assessment Framework. Known from ICER’s site; not read in full.

Links checked 9 October 2026

These are the sources the template drew on. None of their authors or issuers has reviewed it.

About the Panel service

Each panelist answers in their own voice, then the discussion is drawn together. You get the question and who was in the room, every position in full, what they agreed on, where they split, and what follows. Disagreements are written down rather than smoothed into a consensus nobody actually holds, because the split is usually the part you needed.

To edit a saved template, open New → Panel → From template, or the library rail on the service form.